Ultrase ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	3

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00880100 (ClinicalTrials.gov)	April 2009	9/4/2009	Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)	Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old	Cystic Fibrosis;Pancreatic Insufficiency	Drug: Ultrase® MT12	Forest Laboratories	NULL	Completed	2 Years	6 Years	All	49	Phase 3	United States
2	NCT00513682 (ClinicalTrials.gov)	July 2007	7/8/2007	Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)	Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)	Cystic Fibrosis;Pancreatic Insufficiency	Drug: Ultrase® MT20	Forest Laboratories	NULL	Completed	7 Years	11 Years	All	9	Phase 3	United States
3	NCT00408317 (ClinicalTrials.gov)	November 2006	4/12/2006	Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)	A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF)	Cystic Fibrosis;Exocrine Pancreatic Insufficiency	Drug: Ultrase® MT20;Drug: Placebo	Forest Laboratories	NULL	Completed	7 Years	N/A	All	36	Phase 3	United States